BIOFRONTERA AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.334 EUR | +1.83% |
|
+7.05% | -16.71% |
| 11/03 | Biofrontera Files Prospectus for Potential Secondary Stock Offerings | MT |
| 05/03 | Medicus Pharma Names COO | MT |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 159.5 | 223.3 | 206.3 | 145.6 | 83.94 | 97.31 |
| Enterprise Value (EV) 1 | 160.9 | 217.5 | 218.1 | 153 | 80.33 | 92.43 |
| P/E ratio | -9.82 x | -24.7 x | -27.9 x | -12.7 x | 2.18 x | -1.98 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 13.3 x | 10.6 x | 6.6 x | 4.8 x | 2.92 x | 3.78 x |
| EV / Revenue | 13.4 x | 10.3 x | 6.98 x | 5.04 x | 2.79 x | 3.59 x |
| EV / EBITDA | -12.2 x | -12.3 x | -10.2 x | -101 x | -5.15 x | 52 x |
| EV / FCF | -17 x | -23.4 x | -14.8 x | -83.8 x | 104 x | -12.1 x |
| FCF Yield | -5.9% | -4.26% | -6.75% | -1.19% | 0.97% | -8.26% |
| Price to Book | 47.2 x | 13.7 x | 20.7 x | 19.7 x | 1.45 x | 4.78 x |
| Nbr of stocks (in thousands) | 38,416 | 44,573 | 44,849 | 47,748 | 56,717 | 63,807 |
| Reference price 2 | 4.151 | 5.010 | 4.600 | 3.050 | 1.480 | 1.525 |
| Announcement Date | 28/04/18 | 29/04/19 | 21/04/20 | 12/04/21 | 30/04/22 | 28/04/23 |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales 1 | 12.02 | 21.11 | 31.26 | 30.35 | 28.79 | 25.74 |
| EBITDA 1 | -13.17 | -17.74 | -21.34 | -1.518 | -15.6 | 1.778 |
| EBIT 1 | -13.93 | -18.48 | -23.38 | -5.61 | -15.88 | 1.591 |
| Operating Margin | -115.88% | -87.54% | -74.77% | -18.49% | -55.17% | 6.18% |
| Earnings before Tax (EBT) 1 | -16.1 | -19.27 | -4.777 | -12.7 | 35.68 | -43.21 |
| Net income 1 | -16.1 | -8.878 | -7.358 | -13.02 | 38.32 | -44.17 |
| Net margin | -133.9% | -42.06% | -23.53% | -42.92% | 133.11% | -171.6% |
| EPS 2 | -0.4229 | -0.2032 | -0.1646 | -0.2404 | 0.6800 | -0.7700 |
| Free Cash Flow 1 | -9.488 | -9.275 | -14.72 | -1.824 | 0.7758 | -7.63 |
| FCF margin | -78.9% | -43.94% | -47.07% | -6.01% | 2.69% | -29.65% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | 2.02% | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 28/04/18 | 29/04/19 | 21/04/20 | 12/04/21 | 30/04/22 | 28/04/23 |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 |
|---|---|---|---|---|---|
| Net sales 1 | 7.615 | 5.379 | 10.31 | 6.566 | 8.51 |
| EBITDA | - | - | - | - | - |
| EBIT | -3.494 | -4.991 | -22.77 | 1.152 | - |
| Operating Margin | -45.88% | -92.79% | -220.74% | 17.54% | - |
| Earnings before Tax (EBT) 1 | -3.959 | -5.384 | 50.31 | -28.1 | -7.961 |
| Net income 1 | -3.995 | -5.8 | 52.99 | -28.1 | -8.645 |
| Net margin | -52.46% | -107.83% | 513.77% | -427.96% | -101.59% |
| EPS | -0.0700 | -0.1000 | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 19/08/21 | 17/11/21 | 30/04/22 | 17/05/22 | 19/08/22 |
1EUR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 1.44 | - | 11.8 | 7.33 | - | - |
| Net Cash position 1 | - | 5.84 | - | - | 3.61 | 4.88 |
| Leverage (Debt/EBITDA) | -0.1095 x | - | -0.5523 x | -4.828 x | - | - |
| Free Cash Flow 1 | -9.49 | -9.27 | -14.7 | -1.82 | 0.78 | -7.63 |
| ROE (net income / shareholders' equity) | -168% | -90% | -55.9% | -150% | 104% | -113% |
| ROA (Net income/ Total Assets) | -39.8% | -39.2% | -30% | -6.11% | -14.9% | 1.82% |
| Assets 1 | 40.42 | 22.67 | 24.55 | 213.1 | -256.9 | -2,430 |
| Book Value Per Share 2 | 0.0900 | 0.3700 | 0.2200 | 0.1500 | 1.020 | 0.3200 |
| Cash Flow per Share 2 | 0.2900 | 0.4400 | 0.2500 | 0.3500 | 0.1200 | 0.1000 |
| Capex 1 | 0.4 | 0.51 | 1.85 | 0.77 | 0.63 | 0.98 |
| Capex / Sales | 3.3% | 2.43% | 5.93% | 2.55% | 2.19% | 3.81% |
| Announcement Date | 28/04/18 | 29/04/19 | 21/04/20 | 12/04/21 | 30/04/22 | 28/04/23 |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -16.71% | 22.75M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- B8F Stock
- Financials Biofrontera AG
